Compare THRY & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | THRY | VYGR |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.6M | 193.5M |
| IPO Year | 2020 | 2015 |
| Metric | THRY | VYGR |
|---|---|---|
| Price | $1.15 | $2.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $4.00 | ★ $14.89 |
| AVG Volume (30 Days) | 541.4K | ★ 739.1K |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.50 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $785,015,000.00 | $10,135,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $129.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.18 | $1.89 |
| 52 Week High | $12.57 | $5.19 |
| Indicator | THRY | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 21.60 | 25.01 |
| Support Level | N/A | N/A |
| Resistance Level | $4.22 | $4.29 |
| Average True Range (ATR) | 0.09 | 0.13 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 3.12 | 12.72 |
Thryv Holdings Inc is dedicated to supporting local, independent service-based businesses and emerging franchises by providing a cloud-based software platform, and marketing solutions to entrepreneurs. The group are provider of SaaS all-in-one small business management software in addition to providing print and digital marketing solutions to SMBs. Its solutions enable small and medium-sized business clients to attract and generate new business leads, manage their customer relationships efficiently with artificial intelligence (AI) tools and automation. The group has two business segments; Thryv SaaS deriving maximum revenue and Thryv Marketing Services.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.